Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.48 |
| ▸ | PRKDC | P78527 | 2/20 | 0.48 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.48 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 15/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611096 | 1.00 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL17235730 | 0.91 | BTK (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL17911471 | 0.89 | TNK2 (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL17235870 | 0.85 | BTK (0.53) | BTK | |
| SCHEMBL28893630 | 0.83 | BTK (0.41) | BTK | |
| SCHEMBL200349 | 0.81 | NUDT14 (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL19731630 | 0.81 | BTK (0.47) | BTK | |
| SCHEMBL30387716 | 0.81 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| Hydrochloric Acid SCHEMBL29439185 | 0.80 | NUDT14 (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL19385334 | 0.79 | LCK (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3181567-B9 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240174676-A1 | Pyrazolopyrimidine compounds as kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20220073522-A1 | Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220073522-A1 | Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| WO-2021216696-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND OTHER DISORDERS INVOLVING CYTOKINE STORM USING BTK INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-11040980-B2 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040980-B2 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200190092-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200190092-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-9994576-B2 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2892900-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3181567-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160251358-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9266895-B2 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2892900-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20150094295-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-04-02 | — | — | US | disclosed |
| US-8940744-B2 | Pyrazolopyrimidine compounds as kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140364410-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2014-12-11 | — | — | US | disclosed |
| WO-2014039899-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040980-B2 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | BTK, LCK, SYK | PIK3CD 31/4885PIK3CA 22/4885PIK3CB 38/4885 |
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | BTK, TEC, SYK | PIK3CD 214/4885PIK3CA 370/4885PIK3CB 328/4885 |
| US-20160251358-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, SYK | PIK3CD 76/4885PIK3CA 30/4885PIK3CB 64/4885 |
| US-20200190092-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS | BTK, SYK, LCK | PIK3CD 32/4885PIK3CA 16/4885PIK3CB 34/4885 |
| US-20140364410-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, SYK | PIK3CD 76/4885PIK3CA 30/4885PIK3CB 64/4885 |
| US-20150094295-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, SYK | PIK3CD 73/4885PIK3CA 31/4885PIK3CB 65/4885 |
| US-20220073522-A1 | Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors | BTK, SYK, LCK | PIK3CD 32/4885PIK3CA 16/4885PIK3CB 34/4885 |
| US-20240174676-A1 | Pyrazolopyrimidine compounds as kinase Inhibitors | BTK, LCK, LYN | PIK3CD 101/4885PIK3CA 55/4885PIK3CB 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.